Td Waterhouse Canada Inc. Genmab A/S Transaction History

Td Waterhouse Canada Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$26.43 - $32.77 $189,476 - $234,928	-7,169 Closed	0 $0
Q4 2023 Feb 12, 2024	SELL	$27.94 - $35.44 $37,299 - $47,312	-1,335 Reduced 15.7%	7,169 $232 Million
Q3 2023 Nov 13, 2023	BUY	$35.27 - $42.24 $3,139 - $3,759	89 Added 1.06%	8,504 $297 Million
Q2 2023 Nov 13, 2023	BUY	$37.4 - $42.94 $241,192 - $276,920	6,449 Added 328.03%	8,415 $326 Million
Q1 2023 Nov 13, 2023	BUY	$34.88 - $43.22 $51,831 - $64,224	1,486 Added 309.58%	1,966 $74.9 Million

Q4 2022 Nov 13, 2023	BUY	$33.8 - $47.06 $7,841 - $10,917	232 Added 93.55%	480 $22 Million
Q2 2022 Nov 13, 2023	BUY	$26.83 - $38.57 $804 - $1,157	30 Added 13.76%	248 $9.5 Million
Q1 2022 Nov 13, 2023	SELL	$30.95 - $39.68 $1.84 Million - $2.36 Million	-59,500 Reduced 99.63%	218 $8.88 Million
Q4 2021 Nov 13, 2023	BUY	$35.87 - $47.12 $2.14 Million - $2.81 Million	59,718 New	59,718 $2.31 Billion

241

47.6M

31.3K

38.7K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $18.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Td Waterhouse Canada Inc., based on Form 13F filings with the SEC.

Stay updated on Td Waterhouse Canada Inc. with notifications on news.